Merck

Merck confirms diabetes retreat

Merck confirms diabetes retreat

By Kirsty Barnes

Merck Serono intends to forge ahead with severing its investment in
diabetes and either sell or partner out its existing research and
development (R&D) activities in this field, which it no longer
feels able to compete in effectively.

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All suppliers